Today, excessive nutrition and sedentary life have brought along many chron-ic diseases such as obesity and diabetes. As is known, obesity is a disorder of both energy metabolism and appetite regulation. In re-cent studies, it has been reported that AMPK regu-lates the metabolic energy balance as well as governs appetite control. When AMPK is activated, anabol-ic reactions are inhibited, while catabolic reactions are activated to produce energy. In addition to many pharmacological drugs and nutritional supplements, exercise activates AMPK and enhances the translo-cation of the glucose trans-porter (GLUT4) protein, which provides insulin-independent cellular glu-cose uptake. AMPK is an essential intracellular sensor against obesity because when AMP and LKB1 acti-vate AMPK, the use of body fat stores will be en-couraged to produce energy. Appetite-stimulating and suppressing agents act on AMPK to regulate both food intake and body weight control. When appe-tite suppressors such as leptin, insulin, metformin, inhibit AMPK leucine, and berberine, the expression of orexigenic neuropeptides are decreased while the expression of anorexigenic neuropeptides is increased. Understanding the mecha-nisms controlled by the hypothalamic AMPK is crucial for developing ef-fective nutritional strategies for the treatment of nutri-tional intake disorders such as obesity, diabetes mellitus, cardiovascular disease, hypertension and cancer.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors keep the copyrights of the published materials with them, but the authors are aggee to give an exclusive license to the publisher that transfers all publishing and commercial exploitation rights to the publisher. The puslisher then shares the content published in this journal under CC BY-NC-ND license.